Group 1 - The company announced the completion of its share repurchase plan, having repurchased a total of 3,306,180 shares, which represents 0.5049% of the current total share capital [2]

Core Viewpoint - The company, Yingke Medical (300677.SZ), has completed its share repurchase plan, acquiring a total of 3,306,180 shares, which represents 0.5049% of its current total share capital [1] Summary by Relevant Sections - **Share Repurchase Details** - The company repurchased shares through a dedicated securities account via centralized bidding [1] - The total amount spent on the repurchase was approximately RMB 80,000,705.08, excluding transaction fees [1] - The highest transaction price was RMB 36.83 per share, while the lowest was RMB 20.06 per share [1] - **Current Share Capital** - As of September 18, 2025, the total share capital of the company is 654,793,743 shares [1]

Core Viewpoint - The company, Yingke Medical (300677.SZ), has completed its share repurchase plan, acquiring a total of 3,306,180 shares, which represents 0.5049% of its current total share capital [1] Summary by Relevant Sections - **Share Repurchase Details** - The company repurchased shares through a dedicated securities account via centralized bidding [1] - The total amount spent on the repurchase was approximately RMB 80,000,705.08, excluding transaction fees [1] - The highest transaction price was RMB 36.83 per share, while the lowest was RMB 20.06 per share [1] - **Current Share Capital** - The total share capital of the company as of September 18, 2025, is 654,793,743 shares [1]

Company Summary - Inke Medical (SZ 300677) announced on September 19 that it has repurchased approximately 3.31 million shares, accounting for 0.5049% of the company's total share capital, with a total transaction amount of approximately RMB 80 million [1] - The share repurchase was conducted through a special securities account via centralized bidding, with the highest transaction price at RMB 36.83 per share and the lowest at RMB 20.06 per share [1] - As of the report, Inke Medical's market capitalization stands at RMB 23.3 billion [1] Industry Summary - For the fiscal year 2024, Inke Medical's revenue composition is entirely from medical devices, with a 100% contribution from this segment [1]

本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1、英科医疗科技股份有限公司（以下简称"公司"）回购股份 方案实施结果：截至 2025 年 9 月 18 日，公司根据本次回购股份方案 通过股份回购专用证券账户以集中竞价交易方式累计回购公司股份 3,306,180 股，占公司当前总股本的 0.5049%，最高成交价为 36.83 元 /股，最低成交价为 20.06 元/股，成交总金额为人民币 80,000,705.08 元（不含交易费用）。 2、截至本公告披露日，公司本次股份回购方案实施完毕。公司 本次回购股份的资金来源、使用资金总额、回购方式、回购价格及回 购实施期限等，与公司董事会审议通过的回购方案不存在差异。公司 实际回购金额已达回购方案中的回购资金总额下限，且未超过回购资 金总额上限，本次回购符合公司既定的回购股份方案及相关法律法规 的要求。 公司于 2024 年 9 月 19 日召开第三届董事会第二十五次会议和第 证券代码：300677 证券简称：英科医疗 公告编号：2025-131 英科医疗科技股份有限公司 关于公司回购股份实施结果的公告 ...

Core Viewpoint - The stock of Yingke Medical (300677) has shown a positive performance with a closing price of 37.05 yuan, reflecting a 1.51% increase on September 16, 2025, amidst varying capital flows from different investor groups [1][2]. Financial Performance - Yingke Medical reported a main revenue of 4.913 billion yuan for the first half of 2025, representing an 8.9% year-on-year increase [3]. - The net profit attributable to shareholders was 710 million yuan, up 21.02% year-on-year [3]. - The company's second-quarter revenue was 2.42 billion yuan, a 4.79% increase year-on-year, while the net profit for the same period was 358 million yuan, reflecting a 2.55% increase year-on-year [3]. - The company's gross profit margin stood at 24.23%, with a net profit margin of 14.79% [3]. Market Position - Yingke Medical's total market capitalization is 24.26 billion yuan, ranking 8th in the medical device industry [3]. - The company has a price-to-earnings ratio (P/E) of 17.07, significantly lower than the industry average of 69.34, indicating a potentially undervalued stock [3]. - The return on equity (ROE) is 4.03%, which is higher than the industry average of 1.8% [3]. Capital Flow Analysis - On September 16, 2025, the net inflow of main funds was 16.699 million yuan, accounting for 2.9% of the total transaction volume [1][2]. - Retail investors experienced a net outflow of 48.3817 million yuan, representing 8.39% of the total transaction volume [1][2]. - Over the past five days, the stock has seen fluctuations in capital flow, with significant net outflows from retail investors on multiple days [2]. Institutional Ratings - In the last 90 days, six institutions have given a buy rating for Yingke Medical, with an average target price of 33.24 yuan [4].

Core Viewpoint - On September 15, a total of 16 listed companies had their restricted shares unlocked, with a total market value of approximately 17.991 billion yuan [1] Group 1: Companies and Their Restricted Shares - Shaanxi Guo Power (陕鼓动力) unlocked 435,600 shares under equity incentive restrictions [1] - Chuangli Group (创力集团) unlocked 3.936 million shares under equity incentive restrictions [1] - Shengquan Group (圣泉集团) unlocked 478,500 shares under equity incentive restrictions [1] - Yingke Medical (英科医疗) unlocked 995,400 shares under equity incentive restrictions [1] - Ruixin Microelectronics (瑞芯微) unlocked 4,500 shares under equity incentive restrictions [1] - Tongcheng New Materials (彤程新材) unlocked 1.5893 million shares under equity incentive restrictions [1] - Softcom Power (软通动力) unlocked 27.3 million shares with an extended lock-up period [1] - Weiman Sealing (唯万密封) unlocked 66.672 million shares prior to issuance restrictions [1] - Wuxi Zhenhua (无锡振华) unlocked 1.005 million shares under equity incentive restrictions [1] - Hangyu Technology (航宇科技) unlocked 798,600 shares [1] - Gaoling Information (高凌信息) unlocked 40 million shares [1] - Weijie Chuangxin (唯捷创芯) unlocked 8.5394 million shares [1] - Silin Jie (思林杰) unlocked 24.5305 million shares [1] - Kejie Intelligent (科捷智能) unlocked 20 million shares [1] - Juquan Technology (钜泉科技) unlocked 39.8841 million shares [1] - Shengke Communication (盛科通信) unlocked 1.5 million shares [1]

Core Viewpoint - The stock of Yingke Medical (300677) has shown a slight decline, with significant net outflow of main funds, while retail investors have shown net inflow, indicating mixed market sentiment towards the company [1][2]. Financial Performance - As of the latest report, Yingke Medical's total revenue for the first half of 2025 reached 4.913 billion yuan, representing a year-on-year increase of 8.9% [3]. - The net profit attributable to shareholders for the same period was 710 million yuan, up 21.02% year-on-year [3]. - The company's second-quarter revenue was 2.42 billion yuan, with a year-on-year increase of 4.79%, while the net profit for the quarter was 358 million yuan, up 2.55% year-on-year [3]. - The company's gross profit margin stands at 24.23%, which is significantly lower than the industry average of 51.85% [3]. Market Position - Yingke Medical has a total market capitalization of 24.168 billion yuan, ranking 8th in the medical device industry [3]. - The company has a price-to-earnings ratio (P/E) of 17.01, which is favorable compared to the industry average of 67.38 [3]. - The return on equity (ROE) for Yingke Medical is 4.03%, which is higher than the industry average of 1.8% [3]. Fund Flow Analysis - On September 11, 2025, the main funds experienced a net outflow of 60.7557 million yuan, accounting for 12.5% of the total transaction volume [1][2]. - Retail investors showed a net inflow of 45.1347 million yuan, representing 9.29% of the total transaction volume on the same day [1][2]. - Over the past five days, the stock has seen fluctuating fund flows, with notable inflows and outflows from both main and retail investors [2].

证券代码：300677 证券简称：英科医疗 公告编号：2025-130 英科医疗科技股份有限公司 关于为子公司提供担保事项的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 公司名称：山东英科医疗制品有限公司 统一社会信用代码：91370781561439654L 英科医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日、2025 年 5 月 26 日分别召开的第四届董事会第二次（定期） 会议、第四届监事会第二次（定期）会议以及 2024 年度股东大会， 审议通过了《关于公司及子公司向银行申请授信额度及担保事项的议 案》。为满足公司及子公司的生产经营需要，公司及子公司拟向银行 等金融机构申请综合授信的额度以及金融衍生品交易风险限额的总 额（以下简称"授信额度"）不超过 360 亿元人民币，对其担保总额 不超过 360 亿元人民币，授权期限自公司 2024 年度股东大会审议通 过之日起至下一年度股东大会召开时止。具体内容详见刊登于巨潮资 讯网（www.cninfo.com.cn）的《关于公司及子公司向银行申请授信额 度及担保事项的公告》《 ...

Core Viewpoint - The announcement from Yingke Medical indicates that the controlling shareholder, Liu Fangyi, has pledged a portion of his shares for personal financial needs, which may reflect liquidity issues or personal investment strategies [2] Group 1: Share Pledge Details - Liu Fangyi has pledged 1,690,000 shares, which represents 0.73% of his total holdings and 0.26% of the company's total share capital [2] - The pledge is made to Guojin Securities Asset Management Co., Ltd. [2] - The purpose of the pledge is stated as personal funding requirements [2]